- Home
- JBDI vs CLGN Comparison
JBDI vs CLGN Comparison
Compare JBDI & CLGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JBDI
- CLGN
- Stock Information
- Founded
- JBDI 1983
- CLGN 2004
- Country
- JBDI Singapore
- CLGN Israel
- Employees
- JBDI N/A
- CLGN N/A
- Industry
- JBDI
- CLGN Industrial Specialties
- Sector
- JBDI
- CLGN Health Care
- Exchange
- JBDI Nasdaq
- CLGN Nasdaq
- Market Cap
- JBDI 28.7M
- CLGN 33.8M
- IPO Year
- JBDI 2024
- CLGN N/A
- Fundamental
- Price
- JBDI $1.85
- CLGN $3.09
- Analyst Decision
- JBDI
- CLGN Strong Buy
- Analyst Count
- JBDI 0
- CLGN 2
- Target Price
- JBDI N/A
- CLGN $11.50
- AVG Volume (30 Days)
- JBDI 4.1M
- CLGN 12.6K
- Earning Date
- JBDI 01-01-0001
- CLGN 08-20-2025
- Dividend Yield
- JBDI N/A
- CLGN N/A
- EPS Growth
- JBDI N/A
- CLGN N/A
- EPS
- JBDI N/A
- CLGN N/A
- Revenue
- JBDI $9,017,000.00
- CLGN $2,402,000.00
- Revenue This Year
- JBDI N/A
- CLGN $1,617.28
- Revenue Next Year
- JBDI N/A
- CLGN $83.54
- P/E Ratio
- JBDI N/A
- CLGN N/A
- Revenue Growth
- JBDI N/A
- CLGN 248.62
- 52 Week Low
- JBDI $0.49
- CLGN $1.31
- 52 Week High
- JBDI $3.00
- CLGN $5.00
- Technical
- Relative Strength Index (RSI)
- JBDI 57.59
- CLGN 65.56
- Support Level
- JBDI $1.37
- CLGN $2.46
- Resistance Level
- JBDI $2.15
- CLGN $3.18
- Average True Range (ATR)
- JBDI 0.37
- CLGN 0.20
- MACD
- JBDI 0.00
- CLGN 0.04
- Stochastic Oscillator
- JBDI 29.45
- CLGN 88.74
About JBDI JBDI Holdings Limited Ordinary Shares
JBDI Holdings Ltd is a supplier of Reconditioned and new Containers in Singapore. Its products include Reconditioned and new steel drums, plastic drums, carboys and IBCs.
About CLGN CollPlant Biotechnologies Ltd
CollPlant Biotechnologies Ltd is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs and medical aesthetics. Its products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing. The revenues include income from business collaborators and sales of the BioInk product for the development of 3D bioprinting of organs and tissues, sales of rhCollagen for the medical aesthetics market, and sales in Europe of the products for tendinopathy and wound healing. The company operates in United States, which derives key revenue, Canada, Europe and Other, and Israel.